-+ 0.00%
-+ 0.00%
-+ 0.00%

Daiichi Sankyo’s Enhertu wins CHMP backing for EU adjuvant use in HER2-positive early breast cancer

PUBT·09/18/2026 12:00:39
Listen to the news
Daiichi Sankyo’s Enhertu wins CHMP backing for EU adjuvant use in HER2-positive early breast cancer
  • EU drug regulator panel CHMP backed Enhertu for adjuvant use in HER2-positive early breast cancer with residual invasive disease.
  • Opinion supports Daiichi Sankyo, partner AstraZeneca, ahead of a European Commission decision on marketing authorization.
  • DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death versus T-DM1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609180800BIZWIRE_USPR_____20260917_BW458618) on September 18, 2026, and is solely responsible for the information contained therein.